FIA
KALV

FNY Investment Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

FNY Investment Advisers’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-595
Closed -$13K – 1017
2019
Q2 		$13K Buy
+595
New +$14K ﹤0.01% 569

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FNY Investment Advisers's KALV Position: Q3 2019 in Review

FNY Investment Advisers sold out of KalVista Pharmaceuticals (KALV) in Q3 2019, closing a stake of 595 shares — an estimated $13K sold.

FNY Investment Advisers first reported a position in KALV in Q2 2019 and held it in 1 quarter. The position peaked at $13K in Q2 2019. 76 funds tracked by Wall St. Rank hold KALV as of Q3 2019.

  • FNY Investment Advisers reported no remaining KalVista Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 595 KalVista Pharmaceuticals shares in Q3 2019, an estimated $13K.
  • FNY Investment Advisers first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • FNY Investment Advisers's KalVista Pharmaceuticals position peaked at $13K in Q2 2019.
  • 76 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2019.

Based on FNY Investment Advisers's 13F filing for Q3 2019, filed 25 Oct 2019.